<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00327678</url>
  </required_header>
  <id_info>
    <org_study_id>GRAALL 2005</org_study_id>
    <nct_id>NCT00327678</nct_id>
  </id_info>
  <brief_title>Treatment of Acute Lymphoblastic Leukemia (ALL) in Younger Adults</brief_title>
  <official_title>Young Adult With Acute Lymphoblastic Leukemia (ALL) : a Multicentric Protocol. GRAALL 2005 : T ALL or B ALL Non Ph GRAALL 2005 R : B ALL Non Ph CD20+ GRAAPH 2005 : ALL Ph</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Group for Research in Adult Acute Lymphoblastic Leukemia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multicenter trial of treatment for young ALL patients. All ALL patients will
      receive the same steroid pre-phase in order to evaluate sensitivity or resistance. Then,
      patients will be included into 3 specific trials according to biological features
      (immunophenotype, cytogenetics, and molecular biology).

      Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) 2005:

        -  T ALL or B ALL non Ph (N=810 patients planned).

        -  GRAALL 2005 R: B ALL non Ph CD20+ (N=220 patients planned).

        -  GRAAPH 2005: ALL Ph+ (N=270 patients planned)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      GRAALL 2005: T ALL or B ALL non Ph

      Randomization between standard versus intensified cyclophosphamide administration during a
      4-drug, 4 week chemotherapy and late intensification.

      (N=810 patients planned)

      GRAALL 2005 R: B ALL non Ph CD20+

      Randomization between standard versus intensified cyclophosphamide administration during a
      4-drug, 4 week chemotherapy and late intensification.

      Randomization between Mabthera (rituximab) or no Mabthera during all induction and
      consolidation courses.(N=220 patients planned)

      Allogenic transplantation will be performed depending on unfavourable risk factors.

      GRAAPH 2005: ALL Ph

      Randomization between an imatinib-based induction and a chemotherapy + imatinib induction.
      (N=270 patients planned)

      Allogenic transplantation will be systematically performed in the presence of related or
      unrelated donors.

      Autologous transplantation could be performed in the absence of a donor in case of Molecular
      Residual Disease (MRD) ≤ 10-4.

      Consolidation therapy will be performed in the absence of a donor in case of MRD &gt; 10-4.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event free survival for all patients</measure>
    <time_frame>January 2014</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>GRAAPH: Percentage of patients with minimum residual disease (MRD) &lt; 10-4 after induction and/or consolidation (= salvage)</measure>
    <time_frame>January 2014</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>CR in 1 or 2 courses</measure>
    <time_frame>January 2014</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death in induction</measure>
    <time_frame>January 2014</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>January 2014</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death in first CR</measure>
    <time_frame>January 2014</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse</measure>
    <time_frame>January 2014</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse free survival</measure>
    <time_frame>January 2014</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>January 2014</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">1080</enrollment>
  <condition>Leukemia, Lymphocytic</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imatinib Mesylate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-59 years

          -  ALL newly diagnosed (blast &lt; 20%)

          -  Central Nervous System (CNS) positive or negative

          -  Signed written informed consent

          -  For GRAAPH trial only: t(9;22) or BCR- ABL positive

        Exclusion Criteria:

          -  Lymphoblastic lymphoma

          -  ALL 3

          -  Chronic myeloid leukemia

          -  Severe organ condition
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>HERVE DOMBRET, MD, PHD</last_name>
    <role>Study Chair</role>
    <affiliation>GRAALL Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Group for Research in Adult Acute Lymphoblastic Leukemia - GRAALL -</name>
      <address>
        <city>Lyon</city>
        <zip>69</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2006</study_first_submitted>
  <study_first_submitted_qc>May 16, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 18, 2006</study_first_posted>
  <last_update_submitted>June 23, 2016</last_update_submitted>
  <last_update_submitted_qc>June 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ALL,</keyword>
  <keyword>young patients,</keyword>
  <keyword>chemotherapy,</keyword>
  <keyword>Mabtera,</keyword>
  <keyword>Imatinib,</keyword>
  <keyword>allogeneic transplant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

